INCLUSION CRITERIA:

          -  Age ≥ 18 years

          -  Histologically confirmed diagnosis of unresectable stage III or metastatic melanoma
             (stage IIIC to IV per American Joint Committee on Cancer [AJCC])

          -  Documented evidence of BRAF V600 mutation.

          -  Newly obtained tumor biopsy at baseline, and patient agrees to a mandatory biopsy at
             the time of progression, if not medically contraindicated.

          -  Evidence of measurable disease, as determined by RECIST v1.1.

        INCLUSION CRITERIA for triple combinations:

        Progressive disease following prior treatment with LGX818/MEK162 combination. PRINCIPAL
        EXCLUSION CRITERIA Symptomatic or untreated leptomeningeal disease.

          -  Symptomatic brain metastases. Patients previously treated or untreated for brain
             metastases that are asymptomatic in the absence of corticosteroid therapy or on a
             stable dose of steroids for four weeks are allowed to enroll. Brain metastases must be
             stable at least 4 weeks with verification by imaging (e.g. brain MRI completed at
             screening demonstrating no current evidence of progressive brain metastases). Patients
             are not permitted to receive enzyme inducing anti-epileptic drugs.

          -  Patients who have developed brain metastases during Part I of the study may continue
             to Part II upon discussion with Novartis Medical Monitor. The brain metastasis must be
             either asymptomatic or treated and stable for at least 4 weeks and on a stable or
             tapering dose of steroids for at least 2 weeks. Patients with brain metastasis are not
             eligible for the combination with LEE011.

          -  Known acute or chronic pancreatitis.

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
             or hypercoagulability syndromes);

          -  Clinically significant cardiac disease including any of the following:

          -  CHF requiring treatment (NYH grade ≥ 2),

          -  LVEF < 50% as determined by MUGA scan or ECHO

          -  History or presence of clinically significant ventricular arrhythmias or atrial
             fibrillation

          -  Clinically significant resting bradycardia

          -  Unstable angina pectoris ≤ 3 months prior to starting study drug

          -  Acute Myocardial Infarction (AMI) ≤ 3 months prior to starting study drug,

          -  QTcF > 480 msec. Patients with any of the following laboratory values at

        Screening/baseline:

          -  Absolute neutrophil count (ANC) <1,500/mm3 [1.5 x 109/L]

          -  Platelets < 100,000/mm3 [100 x 109/L]

          -  Hemoglobin < 9.0 g/dL

          -  Serum creatinine >1.5 x ULN or calculated or directly measured CrCl < 50% LLN (lower
             limit of normal)

          -  Serum total bilirubin >1.5 x ULN

          -  AST/SGOT or ALT/SGPT > 2.5 x ULN, or > 5 x ULN if liver metastases are present

        Additional exclusion criteria for the triple combinations:

        LGX818/MEK162/BKM120:

          -  Patients with fasting glucose > 120 mg/dL or 6.7 mmol/L, and HbA1c > 8 %.

          -  Patient has any of the following mood disorders as judged by the

        Investigator or a Psychiatrist:

          -  Patient has a score ≥ 12 on the PHQ-9 questionnaire

          -  Patient has ≥ CTCAE grade 3 anxiety

        LGX818/MEK162/BGJ398:

          -  History and/or current evidence of significant ectopic mineralization/ calcification
             with the exception of calcified lymph nodes and asymptomatic vascular calcification.

          -  Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/
             band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivits etc.,
             confirmed by ophthalmologic examination

        LGX818/MEK162/LEE011:

          -  Patients with uncontrolled hypertension (please refer to WHO-ISHguidelines) are
             excluded from study.

          -  QTcF >450 ms for males and >470 ms for females Congenital long QT syndrome or family
             history of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3 and
             magnesium levels below the clinically relevant lower limits at study entry

          -  Current evidence of brain metastasis or brain metastasis detected by mandatory CT/MRI
             at screening

          -  PT/INR or aPTT > 1.5xULN

        Other protocol-defined inclusion/exclusion criteria may apply.